早期乳腺癌9次全乳放疗同步瘤床加量的2期试验
NOVEMBER为2期前瞻性非劣效试验,入组103例Tis及T1-3N0早期乳腺癌患者,接受全乳3420 cGy同步瘤床3960 cGy共9次放疗。中位随访51个月无局部复发,24个月美容评分优良率68%,未达预设主要终点,但80%患者较基线无显著美容变化,晚期≥3级毒性未见报告。
要点
- 9次全乳放疗同步瘤床加量局部控制良好,中位随访51个月无局部复发。
- 24个月美容优良率68%,未达预设主要终点,但80%患者较基线无显著变化。
- 晚期≥3级放疗毒性未见报告,仅4例晚期2级事件,患者自报乳房满意度85%。
核心结论
- 9次全乳放疗同步瘤床加量方案局部控制良好、毒性低、患者满意度高,但未达到预设的美容主要终点。
- 作者希望将该方案与英国5次Fast Forward方案(含同步瘤床加量)进行随机对照试验。
研究设计与样本
- 2期前瞻性非劣效试验,2018至2020年经机构审查委员会批准入组103例Tis及T1-3N0乳腺癌患者。
- 放疗方案为全乳3420 cGy、瘤床3960 cGy;主要终点为24个月平均照片美容评分,假设优良率>70%,基线优良率80%,把握度80%,α=0.1。
主要发现
- 患者平均年龄59.5岁(33-82),以浸润性导管癌(75%)、肿瘤≤2cm(88%)、切缘阴性(92%)为主。
- 中位随访51个月,无局部复发,1例同时出现区域(腋窝)和远处(脑)复发。
- 24个月放疗后美容照片优良率68%、一般/差32%;单侧95%精确二项置信区间为59.1%(59.1%-100%),未拒绝无效假设。
- 未报告晚期≥3级放疗毒性事件,仅4例晚期2级事件;Breast-Q调查显示85%女性乳房满意度。
关键数值与推荐
- 全乳放疗3420 cGy,瘤床同步加量至3960 cGy,共9次。
- 主要终点24个月美容优良率假设>70%,实际68%,单侧95%精确二项置信区间59.1%(59.1%-100%)。
- 80%患者较基线无显著美容变化。
临床怎么用
- 该9次方案可作为早期乳腺癌全乳放疗同步瘤床加量的候选短程方案,局部控制好、晚期毒性低。
- 美容结局未达预设终点,实施前需与患者充分沟通美容风险,并等待与5次Fast Forward方案的随机对照结果。
局限性
- 为单臂2期非劣效试验,样本量103例,随访尚不足以评估长期复发与晚期毒性。
- 主要终点美容评估采用照片评分,未达到预设阈值,结论需随机试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE/OBJECTIVES: A phase 2 prospective noninferiority trial evaluating a novel 9 fraction course of whole breast radiation and simultaneous lumpectomy boost. MATERIALS AND METHODS: Tis and T1-3N0 patients enrolled to receive 3420 cGy radiation to the breast with 3960 cGy to the lumpectomy cavity. The primary endpoint was averaged photographic cosmetic scores at 24 months with a hypothesis of >70% good to excellent cosmetic breast scoring 24 months after completing radiation, assuming a baseline excellent/good cosmetic scoring of 80% with an 80% power, α = 0.1. RESULTS: From 2018 to 2020, with institutional review board approval, 103 patients were enrolled. Patients had mostly invasive ductal carcinoma (75%), tumor size ≤ 2cm (88%), negative margins (92%), no lympho-vascular invasion (80%), and estrogen receptor positive (85%). Patients had a mean age of 59.5 years (33-82). With a mean follow-up of 51 months, there were no local recurrences and 1 patient with both regional (axilla) and distant (brain) recurrence. Twenty-four-month post-radiation therapy (RT) cosmetic photos were 68% excellent/good, and 32% fair/poor. The null hypothesis was not rejected with one-sided 95% exact binomial confidence interval of 59.1% (59.1%-100%). There were no reported late ≥grade 3 radiation toxicity events and only 4 patients with late grade 2 events. Patient-reported outcomes utilizing the Breast-Q survey revealed breast satisfaction in 85% of women. CONCLUSIONS: We demonstrate an effective novel 9 fraction whole breast + lumpectomy boost radiation schedule. This trial uses one of the shortest published radiation schedules for a lumpectomy boost. Although we did not meet our prespecified cosmetic endpoint, no significant cosmetic change from baseline was seen in 80% of patients. We demonstrate excellent local control, and patient-reported satisfaction with low RT-related toxicity. We hope to move this concept forward in a randomized trial against the 5-day United Kingdom (UK) Fast Forward regimen, inclusive of a simultaneous lumpectomy cavity boost.
引用
- Poppe MM, Boucher K, Gaffney DK, et al. NOVEMBER, A Phase 2 Trial of a 9-Day Course of Whole Breast Radiation Therapy With a Simultaneous Lumpectomy Boost for Early-Stage Breast Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 40314623. doi:10.1016/j.ijrobp.2025.03.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。